Topical β-blockers for treatment of glaucoma and the risk of Parkinson’s disease
Topical β-blocker use was not associated with an increased risk of PD. These findings suggest that topical β-blockers are a safe therapeutic option, even for patients at potential risk for PD.
Authors
- Assaf Dotan
- Shiri Shulman (ORCID: https://orcid.org/0000-0002-3188-3470)
- Orly Gal‐Or (ORCID: https://orcid.org/0000-0002-3421-4555)
- Noa Geffen
- Sivan Gazit (ORCID: https://orcid.org/0000-0001-9875-3550)
- Itay Gabbay (ORCID: https://orcid.org/0000-0003-4108-061X)
- Nir Giladi (ORCID: https://orcid.org/0000-0003-1482-8522)
- Tal Patalon (ORCID: https://orcid.org/0000-0001-7415-1053)
- Alon Zahavi (ORCID: https://orcid.org/0000-0002-9451-5253)
- Amit Meshi (ORCID: https://orcid.org/0000-0002-7440-0539)
- Yuval Kozlov
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Rabin Medical Center (IL)
- Assuta Medical Center (IL)
- Maccabi Healthcare Services (IL)
Publication Details
- Journal
- British Journal of Ophthalmology
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1136/bjo-2024-326689
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00